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Background: Breast cancer is the most common malignancy in women throughout the world. Mitochondria play
important roles in cellular energy production, free radical generation and apoptosis. Identification of mitochondrial
DNA mutations and/or polymorphisms as cancer biomarkers is rapidly developing in molecular oncology research.
Methods: In this study, the DNA alterations of the mitochondrial ATPase 6 and 8 genes were investigated in 49
breast cancer patients using PCR amplification and direct DNA sequencing on mtDNA. A possible association
between these variants and tumorigenesis was assessed. Furthermore, the impact of non-synonymous substitutions
on the amino acid sequence was evaluated using the PolyPhen-2 software.
Results: Twenty eight distinct somatic mitochondrial DNA variants were detected in tumor tissues but not in the
corresponding adjacent non-tumor tissues. Among these variants, 9 were observed for the first time in breast cancer
patients. The mtDNA variants of A8384 (T7A), T8567C (I14T), G8572A (G16S), A9041G (H172R) and G9055A (A177T)
showed the most significant effects probably due to damaging changes to the resulting protein. Furthermore,
non-synonymous amino acid changing variants were more frequent in the ATPase6 gene compared to the ATPase8 gene.
Conclusion: Our results showed that the ATPase6 gene is more susceptible to variations in breast cancer and may play
an important role in tumorigenesis by changing the energy metabolism level in cancer cells.
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Breast cancer is a major public health problem in women
throughout the world. In 2008, it was the most common
cause of death in women (458,000 deaths) worldwide [1].
Breast cancer is also the most common cancer and the
fifth cause of mortality due to malignancies among Iranian
women [1,2].
The human mitochondrial genome consists of a circular
double-stranded DNA of 16,569 base pairs, including genes
encoding for the electron transport chain (complexes I-IV),
ATP synthase or complex V in oxidative phosphorylation
as well as a displacement loop region, 2 ribosomal RNAs
(16 and 23) and 22 transfer RNAs [3,4]. Variants of* Correspondence: massoudh@nigeb.ac.ir
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distribution, and reproduction in any mediumATPase subunit 6 (8366–8572) and ATPase subunit 8
(8527–9207) in mitochondrial DNA (mtDNA) has been
reported in different types of cancers, including breast,
colon and ovarian [5-7].
The mitochondrion plays a critical role in cellular energy
production [8], carcinogenesis and tumor progression, and
could be a prognostic marker in different cancer types
[5,9-15]. To date, various types of mtDNA alterations, in-
cluding point variants, large deletion and copy number
changes have been reported in breast, colon and ovarian
cancers [5,16]. There is strong evidence that mtDNA
alterations can enhance oxidative stress and the risk of
tumor development as well as tumor initiation, prolifera-
tion [17], metastasis [18-20] and resistance of cancer cells
to apoptosis [21].
Therefore, this study was undertaken to evaluate mito-
chondrial ATPase6 and 8 alterations in tumor and adjacentntral Ltd. This is an Open Access article distributed under the terms of the
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investigated the correlation between the variants in these




Forty-nine breast cancer patients (34–75 years of age with
a median age of 52.43 years) took part in this study. The
patients were referred to the National Cancer Institute
(NCI) at Imam Khomeini Hospital Complex, Tehran, Iran,
from Oct. 2007 to Oct. 2009. Tumor tissue and adjacent
non-tumor tissue samples were obtained from the Iranian
National Tumor Bank (INTB) at NCI. Each specimen
was immediately frozen following resection and stored
at −80°C until DNA extraction. The pathologic changes
in tumor samples were confirmed by two expert patho-
logists as adenocarcinomas according to the American
Joint Committee on Cancer [22]. None of the patients re-
ceived chemotherapy or radiotherapy treatment before
they underwent surgery. All patients were informed on the
aim of the study and signed an informed consent approved
by the INTB Ethical Committee for the genetic analysis.
DNA extraction and PCR
In order to identify the alterations in the mtDNA ATPase6
and ATPase8 genes, PCR-sequencing was performed as
described previously with some modifications [23] Total
genomic DNA was extracted from fresh tumor samples
containing at least 90% neoplastic cells, as well as their
adjacent non-tumor tissues, using the QIAamp Mini
Kit (USA). The sequences of the primers were as follows:
F-ATPase: 5′- CTACGGTCAATGCTCTGAAA -3′ (Acces-
sion No. NC_012920.1, 8161–8180). R-ATPase: 5′-TACT
ATATGATAGGCATGTGA-3′ (9219–9239). PCR ampli-
fication was performed using a ready-to-use PCR master
mix (Sinaclon LTD, Tehran, Iran) in a final volume of
50 μl containing 5 ng of genomic DNA and 0.10 μM of
each primer in a MJ Mini Gradient Thermal Cycler PTC-
1148 (Bio-Rad, USA). PCR amplification was carried out
with the following program: a 5-min pre-PCR incubation
step at 95°C, 35 cycles of 95°C for 60 s, annealing
temperature at 55°C for 1 min and 72°C for 2 min, and a
final extension of 72°C for 10 min. The amplified fragment
(1078 bp) was observed on 1.5% agarose gel.
Sequencing analysis
The PCR products were sequenced using the previously
reported primers [23] on a ABI Prism 3700 automated
sequencer (Applied Biosystems, USA). Sequence analysis
was carried out using the FinchTV 1.4 software (Geospiza,
Inc., USA). The sequences were compared to the human
mtDNA reference sequence (Gene Bank ID: NC_012920.1)
using the BLAST sequence analysis tool (NCBI, Bethesda,USA). The Mitomap database was used to identify mito-
chondrial genome sequence variants.
Prediction of pathogenicity by protein modeling analysis
The impact of non-synonymous (coding) substitutions
in the resulting protein was assessed using PolyPhen-2
(v. 2.2.2) software, a tool for predicting the possible impact
of an amino acid substitution variant on the structure and
function of the corresponding protein, which is interpreted
as benign and damaging effects [24].
Statistical analysis
The correlation between each alteration in the ATPase6
and ATPase8 genes in tumor samples and their adjacent
normal tissue were analyzed by Fisher’s exact test using
statistical package SPSS (v.16.1). The correlation between
the groups was considered statistically significant if the
p-value was less than 0.05. Additionally, for each variant
the odds ratio (OR) and 95% confidence interval (95% CI)
were calculated in order to determine its association to
the increased risk in breast cancer patients. The association
between mtDNA alteration and clinico-pathological cha-
racteristics of breast cancer patients with more than one
missense mutation was evaluated using One-way ANOVA
analysis.
Results
In this study, the complete sequences of the ATPase6
and 8 genes of 49 tumor tissues and adjacent non-tumor
tissues were analyzed in a cohort of breast cancer patients.
The clinico-pathological characteristics of the patients are
summarized in Table 1. From 49 breast cancer cases, 28
mtDNA variants were found in tumor tissues, which were
not present in their adjacent normal tissues. From 28
variants, 23 (82.14%) were found in the ATPase6 gene
and the remaining 5 sequence variants were detected
in the ATPase8 gene. All cases showed variants in the
ATPase6 gene, whereas only 8.16% (4 of 49) cases had
variants in the ATPase8 gene. Among 28 mtDNA alter-
ations, 26 were at the homoplasmic state and the remaining
2 variants were at the heteroplasmic state (Table 2).
However, there was no significant correlation (P > 0.05)
between the ATPase6 and 8 gene variants and the clinico-
pathological characteristics of the patients (Table 1). Our
results indicated that the A8860G variant was detected in
100% of tumor tissue samples compared to adjacent non-
tumor tissues, showing that this alteration may significantly
increase breast cancer risk (P < 0.05). However, the patients’
survival was shorter in cases with more than one mtDNA
non-synomous ATPase variant compared to the patients
with only one mtDNA non-synonymous ATPase variant
(A8860G ) (p =0.051, Table 1).
Furthermore, the damaging impact of an amino acid
substitution on the structure and function of the ATPase6
Table 1 Characterization of clinico-pathological parameters and the frequency of cases with more than one somatic
mtDNA (ATPase6/8) mutation in breast cancer patients
Frequency of patients in each group Patients with more than one somatic mtDNA (ATPase6/8) mutation
Variable n (%) n (%) OR; (95% CI)* P value
Total number of patients 49
















Lymph node status 1.176(0.281-4.926) 1.000
Negative 12(30.8) 4(33.3)
Positive 27(69.2) 10(37)
Lymphatic invasion 1.077(0.281-4.127) 1.000
Negative 18(47.4) 6(33.3)
Positive 20(52.6) 7(35)
Vascular invasion 2.292(0.511-10.284) 1.000
Negative 13(32.5) 4(30.8)
Positive 27(67.5) 10(37)
Estrogen receptor status 0.357(0.075-1.704) 0.222
Negative 8(17.4) 4(50)
Positive 38(82.6) 10(26.3)
Progesterone receptor status 0.938(0.265-3.313) 1.000
Negative 22(48.9) 7(31.8)
Positive 23 (51.1) 7(30.4)






Cancer metastasis 3.056(0.718-13.011) 0.191
Negative 18(38.3) 3(16.7)
Positive 29(61.7) 11(37.9)
Overall survival (5 yr%) 18 of 41(43.9) 3(16.7) 0.218(0.049-0.963) 0.051
*OR; Odds ratio, (95% CI); confidence interval reflects a significance level of 0.05.
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Table 2 Frequency of mtDNA ATPase 6/8 gene sequence alterations in 49 breast cancer patients








Frequency OR; 95% CI*** P Value Reference
1 MT-ATPase8 A8384G 8384 A-G T7A Hm 1 1.021;0.980-1.063 0.315 NR****
2 MT-ATPase6 T8542C 8542 T-C F6L Hm 1 1.021;0.980-1.063 0.315 NR
3 MT-ATPase8 T8542C 8542 T-C C59C Hm 1 1.021; 0.980-1.063 0.315 NR
4 MT-ATPase6 G8557A 8557 G-A A11T Hm 1 1.021; 0.980-1.063 0.315 Colonic crypts cancer [34], Breast cancer [27,28]
5 MT-ATPas8 G8557A 8557 G-A L64L Hm 1 1.021; 0.980-1.063 0.315 Alzheimer's disease [40]
6 MT-ATPase6 T8567C 8567 T-C I14T Hm 1 1.021; 0.980-1.063 0.315 Parkinson's disease [42]
7 MT-ATPas8 T8567C 8567 T-C S68P Hm 1 OR 1.021;: 0.980-1.063 0.315 Parkinson's disease [49]
8 MT-ATPase6 G8572A 8572 G-A G16S Hm 1 OR 1.021; 0.980-1.063 0.315 Thyroid tumor [50]
9 MT-ATPas8 G8572A 8572 G-A G69S Hm 1 1.021; 0.980-1.063 0.315 Colonic crypts cancer [34]
10 MT-ATPase6 C8684T 8684 C-T T53I Hm 1 1.021; 0.980-1.063 0.315 Multiple Sclerosis [51], Ataxia telangiectasia [21],
Huntington [52], Autism [53], Osteosarcoma [54],
11 MT-ATPase6 T8697C 8697 T-C I24T Hm 1 1.021; 0.980-1.063 0.315 Thyroid tumor [50], Multiple Sclerosis [51], Ataxia
telangiectasia [21], Breast cancer [30], Colorectal
adenomatous polyps [40]
12 MT-ATPase6 A8701G 8701 A-G T59A Hm 2 1.043; 0.984-1.105 0.153 Thyroid tumor [50], Ataxia telangiectasia [21],
Breast cancer [27,29], colorectal adenomatous
polyps [38], Osteosarcoma [54]
13 MT-ATPase6 T8777C 8777 T-C F117F Hm 1 1.021; 0.980-1.063 0.315 NR
14 MT-ATPase6 C8794T 8794 C-T H90Y Hm 2 1.043; 0.984-1.105 0.153 Exercise Endurance/Coronary Atherosclerosis risk[32]
15 MT-ATPase6 A8860G 8860 A-G T112A Hm 49 0.000 Colorectal cancer [36,38], Ovarian cancer [37],
Breast cancer [27,29,34], Human glioma cells [33],
Osteosarcoma [54], Leber's hereditary optic
neuropathy [35]
16 MT-ATPase6 T8877C 8877 T-C F117F Hm 3 1.065; 0.992–1.114 0.079 Leber's hereditary optic neuropathy [55]
17 MT-ATPase6 T8881C 8881 T-C S119P Ht 1 1.021; 0.980-1.063 0.315 NR
18 MT-ATPase6 C8910T 8910 C-T F128F Ht 2 1.043; 95% CI: 0.984-1.105 0.153 The southern belt of Siberia population [56]
19 MT-ATPase6 G8950A 8950 G-A V142I Hm 2 1.043; 0.984-1.105 0.153 Huntington [54],LDYT [57]
20 MT-ATPase6 G8994A 8994 G-A L156L Hm 1 1.021; 0.980-1.063 0.315 Ataxia telangiectasia [21], Breast cancer [27],
Colorectal adenomatous polyps [38]
21 MT-ATPase6 C9003A 9003 C-A R159R Hm 1 OR 1.021; 0.980-1.063 0.315 NR
22 MT-ATPase6 A9007G 9007 A-G T161A Hm 1 1.021; 0.980-1.063 0.315 Deafness associated [58]
23 MT-ATPase6 A9041G 9041 A-G H172R Hm 1 1.021; 0.980-1.063 0.315 NR
24 MT-ATPase6 G9055A 9055 G-A A177T Hm 3 1.065; 0.992–1.114 0.079 Colorectal cancer [36], Colorectal adenomatous
polyps [38], Breast cancer [28,30], Non-muscle
invasive bladder cancer [44], Osteosarcoma [54],
















Table 2 Frequency of mtDNA ATPase 6/8 gene sequence alterations in 49 breast cancer patients (Continued)
25 MT-ATPase6 G9085A 9085 C-T P187S Hm 1 1.021; 0.980-1.063 0.315 NR
26 MT-ATPase6 T9090C 9090 T-C S188S Hm 1 1.021; 0.980-1.063 0.315 Colorectal cancer [59] Leber's hereditary optic
neuropathy [60]
27 MT-ATPase6 T9148C 9148 T-C L208L Hm 1 1.021; 0.980-1.063 0.315 Occipital stroke [61]
28 MT-ATPase6 C9168T 9168 C-T F214F Hm 1 1.021; 0.980-1.063 0.315 NR
Abbreviations:
*Missense mutations are in bold.
**Hm: Homoplasmic, Ht: Heteroplasmic.
*** OR; Odds ratio, (95% CI); confidence interval reflects a significance level of 0.05.
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(Table 3). The mtDNA variants A8384 (T7A), T8567C
(I14T), G8572A (G16S), A9041G (H172R) and G9055A
(A177T) showed significant effects on the resulting
protein. However, there was no significant association
between mtDNA alterations and the clinico-pathological
characteristics of breast cancer patients.Discussion
The identification of mitochondrial DNA mutations and/or
polymorphism patterns is rapidly developing in the field of
molecular oncology. A large number of somatic mutations
in the mitochondrial genome have been recently reported
in different types of cancer,luding breast, colon and ovarian
cancers [5,6]. These molecular markers may have potential
implication in cancer research.
Mitochondrial complex V genes play an important role
in ATP production [25] and the apoptosis pathways
[5]. The contribution of mtDNA complex V variants in
cell transformation, elevated ROS production, and tumor
progression has been described previously [26]. Moreover,
efficient programmed cell death needs the molecular
machinery of ATP synthase [27].
The ATPase6 gene, one of the complex V genes, con-
tributes to mtDNA maintenance [25]. Furthermore, the
ATPase8 variants have been detected in rat and humanTable 3 Impact of non-synonymous* (coding) substitutions
on the ATPase6 and 8 genes
Non-synonymous
coding substitutions
Damaging score Benign score
ATPase 6 gene
T8542C( F6L) 0.976 0.917
G8557A (A11T) 0.002 0.004
T8567C (I14T) 0.617 0.280
G8572A (G16S) 0.895 0.498
C8684T (T53I) 0.005 0.005
A8701G (T59A) 0.002 0.005
C8794T (H90Y) 0.002 0.003
A8860G (T112A) 0.000 0.003
T8881C (S119P) 0.325 0.149
G8950A (V142I) 0.000 0.001
A9007G (T161A) 0.994 0.988
A9041G H(172R) 0.854 0.331
G9055A (A177T) 0.854 0.331
ATPase 8 gene
A8384G (T7A) 0.845 0.399
T8542C (S68P) 0.000 0.000
Non-synonymous variants were predicted as damaging and benign (With a score
of 0 to 1) based on effects on the resulting protein using PolyPhen-2 software.
The new variants are in bold format.bladder cancer cells developed through chemically-induced
carcinogenesis [28]. In a meta-analysis study carried out by
Lu et al. a total of 55 variants, comprising 34 missense vari-
ants, 20 silent variants and 1 nonsense variant, were found
in the ATPase6 gene and a total of 9 variants, including 2
missense variants and 7 silent variants, were detected in the
ATPase8 gene [6].
In our study, among 28 distinct somatic variants, 18
were missense variants. Six variants have been previously
reported in breast cancer [29-32] and 9 variants were new,
including 4 missense and 5 silent variants which were
observed for the first time in breast cancer patients.
However, 17 variants were previously reported in other
types of cancers and diseases (Table 2). In addition, more
non-synonymous amino acid changing variants were found
in the ATPase6 gene in comparison with the ATPase8 gene
(Table 2). Our findings suggest that in breast cancer
patients, the ATPase6 gene might be more susceptible to
mutation in comparison to the ATPase8 gene. Shidara
et al. and Kirches reported that ATPase6 gene variants
may enhance cancer progression by preventing apoptosis
pathways [6,33].
The functional role of ATPase6/8 variants in tumori-
genesis is debatable; however, some of these variants are
located in structurally and functionally important regions
of the proteins. For instance, the A8860G alteration in
ATPase6 has been reported as a polymorphism in different
studies [29,31,34-40]. The frequency of this polymorphism
has been reported to be from 79–91.66% in breast cancer
patients [30,31], 75-100% in other types of cancers [38-40]
and 92.85%-100% in neurodegenerative diseases [37,41-43].
Our results indicated that the A8860G variant was present
in 100% of tumor tissue samples. Although this variant
is located in a poorly conserved protein region with no
impact on protein structure based on PolyPhen-2 software
(Table 3), the variation may still contribute to other
mtDNA and nDNA mutations.
The frequency of the G9055A variation has been reported
as either 10.5% [28] or 18.6% [30] in breast cancer patients,
indicating that it may increase the risk of breast cancer pro-
gression (OR: 3.03, 95% CI: 1.63-5.63, P = 0.0004) [32,44].
This variation is located in a conserved protein region
with damaging impact on protein structure (Table 3). Fur-
thermore, the frequency of this polymorphism has been
reported as 10% in pancreatic cancer [45] and as 57% and
100% in tubular and villous adenomas, respectively [40].
Moreover, the high frequency of this variation has been
shown in non-muscle invasive bladder cancer [46]. In
addition, this polymorphism has been reported as a
protective factor (OR: 0.46, 95% CI: 0.22-0.91, P = 0.03)
in Caucasian women with Parkinson’s disease [47]. From
these results, we propose that this mtDNA variation is
unfavorable for neurodegenerative disorders, while having
a protective effect on cancer. According to our results, the
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samples.
A study by Petros et al. indicated that T8993G in
ATPase6 can contribute to tumor growth in nude mice
[48]. Another study showed that cybrids with a T8993G
or T9176 ATPase6 mutation in nude mice can con-
tribute to tumor development by preventing apoptosis
in the early stages of tumor growth [10]. However, weTable 4 MtDNA alterations and clinico-pathological character
missense mutation
Case Locus Variant Frequency Age (Yrs)




BC-10 ATPase6 A8860G 3 55
G8950A
A9041G
BC-19 ATPase6 A8860G 2 42
G9055A
BC-20 ATPase6 A8860G 2 68
A9007G
BC-21 ATPase6 A8860G 2 43
G8950A
BC-23 ATPase6 A8860G 2 36
G9055A
BC-25 ATPase6 A8860G 2 50
C8794T
BC-32 ATPase6 A8860G 2 74
T8881C
BC-35 ATPase6 C8794T 2 75
A8860G
BC-37 ATPase6 A8860G 2 67
G9095A
BC-38 ATPase6 A8701G 3 69
A8860G
T9085C
BC-39 ATPase6 A8701G 2 59
A8860G
BC-41 ATPase6 C8684T 2 51
A8860G
BC-48 ATPase6 T8567C 3 41
ATPase8 T8567C
A8860G
T1–T4: Size and/or extent of the primary tumor; NX: Regional lymph nodes cannot
lymph nodes); N1-N3:Involvement of regional lymph nodes (number and/or extent
from one part of the body to another). There was no significant association betwee
cancer patients.detected none of these mutations in breast cancer
patients.
Based on our results, the existence of more than one
missense variants in some cases with different clinico-
pathological features (Table 4) suggests a synergistic
effect of different mtDNA variations on carcinogenesis.
In conclusion, the high frequency of ATPase6 gene alter-
ations in breast cancer proposes that mitochondrial geneistics of breast cancer patients with more than one
Grade Tumor size (cm) TNM* Stage
III 3 T2N1M0 II
III 2.5 T2N0M1 IV
II 5 T3N2M1 IV
III 1.8 T2N1M1 IV
1.2 T1NXM1 IV
III 10 T3N3M1 IV
II 13 T4N3M1 IV
I 5 T3N1M1 IV
II 5 T3N3M1 IV
II 2 T1N0M0 I
II 3.5 T2N3M1 IV
III 3 T2N0M0 II
II 3.5 T2N0M1 IV
II 4.5 T2N3M1 IV
be evaluated; N0: No regional lymph node involvement (no cancer found in the
of spread); M0:No distant metastasis; M1:Distant metastasis (spread of cancer
n the mtDNA alterations and clinic-pathological characteristics of breast
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changing the energy metabolism in cancer cells, and may
be suggested as molecular biomarkers in breast cancer.
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